Metodología, diagnóstico y terapéutica para el síndrome de piernas inquietas

Translated title of the contribution: Updating restless legs syndrome

Research output: Contribution to journalArticle

Abstract

Restless legs syndrome (RLS) is a common sensorimotor disorder that is usually associated with significant sleep disturbance and daytime complaints potentially leading to increased co-morbid health risks. RLS is diagnosed by fulfilling the following four criteria: (1) an urge to move, usually associated with paresthesias, (2) onset or exacerbation of symptoms at rest, (3) relief of symptoms with movement, and (4) symptoms manifest in a circadian pattern. Adults and children can suffer from RLS and there is a genetic predisposition manifesting with an earlier age of onset of RLS symptoms, usually before the age of 45 years. A variety of conditions may mimic RLS so it is important to differentiate these during evaluation of the patient. Treatment of RLS includes iron supplementation, dopaminergic agents (DA), opioids, benzodiazepines, and anti-epileptic drugs (AEDs). DA demonstrate the largest treatment effect and include the only two FDA-approved drugs in the United States to treat RLS. Iron supplementation in RLS patients who are found to be iron deficient may be beneficial as well. However, each of the treatment options, including the use of DA, must be considered on a case-by-case basis taking into account symptom severity and side effect profiles. Increased recognition and management of RLS, an often debilitating condition, can lead to an improved quality-of-life and potentially improved overall health for the many who suffer from RLS. Copyrigth

Original languageSpanish
Pages (from-to)654-660
Number of pages7
JournalSalud(i)Ciencia
Volume17
Issue number7
StatePublished - Aug 2010

Fingerprint

Restless Legs Syndrome
Dopamine Agents
Iron
Paresthesia
Health
Genetic Predisposition to Disease
Benzodiazepines
Age of Onset
Pharmaceutical Preparations
Opioid Analgesics
Sleep
Therapeutics
Quality of Life

Keywords

  • Augmentation
  • Diagnosis
  • Dopamine
  • Epidemiology
  • Periodic legs movement
  • Restless legs syndrome
  • Treatment

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Metodología, diagnóstico y terapéutica para el síndrome de piernas inquietas. / Chik, Yolanda; Salas, Rachel; Gamaldo, Charlene.

In: Salud(i)Ciencia, Vol. 17, No. 7, 08.2010, p. 654-660.

Research output: Contribution to journalArticle

@article{ed85753c44364ff1b33f2435fa5cb126,
title = "Metodolog{\'i}a, diagn{\'o}stico y terap{\'e}utica para el s{\'i}ndrome de piernas inquietas",
abstract = "Restless legs syndrome (RLS) is a common sensorimotor disorder that is usually associated with significant sleep disturbance and daytime complaints potentially leading to increased co-morbid health risks. RLS is diagnosed by fulfilling the following four criteria: (1) an urge to move, usually associated with paresthesias, (2) onset or exacerbation of symptoms at rest, (3) relief of symptoms with movement, and (4) symptoms manifest in a circadian pattern. Adults and children can suffer from RLS and there is a genetic predisposition manifesting with an earlier age of onset of RLS symptoms, usually before the age of 45 years. A variety of conditions may mimic RLS so it is important to differentiate these during evaluation of the patient. Treatment of RLS includes iron supplementation, dopaminergic agents (DA), opioids, benzodiazepines, and anti-epileptic drugs (AEDs). DA demonstrate the largest treatment effect and include the only two FDA-approved drugs in the United States to treat RLS. Iron supplementation in RLS patients who are found to be iron deficient may be beneficial as well. However, each of the treatment options, including the use of DA, must be considered on a case-by-case basis taking into account symptom severity and side effect profiles. Increased recognition and management of RLS, an often debilitating condition, can lead to an improved quality-of-life and potentially improved overall health for the many who suffer from RLS. Copyrigth",
keywords = "Augmentation, Diagnosis, Dopamine, Epidemiology, Periodic legs movement, Restless legs syndrome, Treatment",
author = "Yolanda Chik and Rachel Salas and Charlene Gamaldo",
year = "2010",
month = "8",
language = "Spanish",
volume = "17",
pages = "654--660",
journal = "Salud (i) Ciencia",
issn = "1667-8982",
publisher = "Sociedad Iberoamericana de Informacion Cientifica",
number = "7",

}

TY - JOUR

T1 - Metodología, diagnóstico y terapéutica para el síndrome de piernas inquietas

AU - Chik, Yolanda

AU - Salas, Rachel

AU - Gamaldo, Charlene

PY - 2010/8

Y1 - 2010/8

N2 - Restless legs syndrome (RLS) is a common sensorimotor disorder that is usually associated with significant sleep disturbance and daytime complaints potentially leading to increased co-morbid health risks. RLS is diagnosed by fulfilling the following four criteria: (1) an urge to move, usually associated with paresthesias, (2) onset or exacerbation of symptoms at rest, (3) relief of symptoms with movement, and (4) symptoms manifest in a circadian pattern. Adults and children can suffer from RLS and there is a genetic predisposition manifesting with an earlier age of onset of RLS symptoms, usually before the age of 45 years. A variety of conditions may mimic RLS so it is important to differentiate these during evaluation of the patient. Treatment of RLS includes iron supplementation, dopaminergic agents (DA), opioids, benzodiazepines, and anti-epileptic drugs (AEDs). DA demonstrate the largest treatment effect and include the only two FDA-approved drugs in the United States to treat RLS. Iron supplementation in RLS patients who are found to be iron deficient may be beneficial as well. However, each of the treatment options, including the use of DA, must be considered on a case-by-case basis taking into account symptom severity and side effect profiles. Increased recognition and management of RLS, an often debilitating condition, can lead to an improved quality-of-life and potentially improved overall health for the many who suffer from RLS. Copyrigth

AB - Restless legs syndrome (RLS) is a common sensorimotor disorder that is usually associated with significant sleep disturbance and daytime complaints potentially leading to increased co-morbid health risks. RLS is diagnosed by fulfilling the following four criteria: (1) an urge to move, usually associated with paresthesias, (2) onset or exacerbation of symptoms at rest, (3) relief of symptoms with movement, and (4) symptoms manifest in a circadian pattern. Adults and children can suffer from RLS and there is a genetic predisposition manifesting with an earlier age of onset of RLS symptoms, usually before the age of 45 years. A variety of conditions may mimic RLS so it is important to differentiate these during evaluation of the patient. Treatment of RLS includes iron supplementation, dopaminergic agents (DA), opioids, benzodiazepines, and anti-epileptic drugs (AEDs). DA demonstrate the largest treatment effect and include the only two FDA-approved drugs in the United States to treat RLS. Iron supplementation in RLS patients who are found to be iron deficient may be beneficial as well. However, each of the treatment options, including the use of DA, must be considered on a case-by-case basis taking into account symptom severity and side effect profiles. Increased recognition and management of RLS, an often debilitating condition, can lead to an improved quality-of-life and potentially improved overall health for the many who suffer from RLS. Copyrigth

KW - Augmentation

KW - Diagnosis

KW - Dopamine

KW - Epidemiology

KW - Periodic legs movement

KW - Restless legs syndrome

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=77957802011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957802011&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77957802011

VL - 17

SP - 654

EP - 660

JO - Salud (i) Ciencia

JF - Salud (i) Ciencia

SN - 1667-8982

IS - 7

ER -